BPC-157 stays a gray-market peptide with no FDA approval. Doctor commentary in mainstream press shapes how patients view it but does not change the rules.

Off-label BPC-157 marketing pieces like this keep the unapproved peptide in consumer view, which may draw more FDA attention to compounders and sellers.

BPC-157 is mostly sold today through gray-market peptide shops. A real drug developer working on it could push the peptide toward formal clinical testing.